Age-Triggered Stem Cells Drive Belly Fat Surge in Middle Age
Scientists identify a new type of stem cell that activates with aging and supercharges belly fat production, opening anti-obesity targets.
Summary
Researchers at City of Hope have identified a newly discovered type of stem cell that appears during aging and dramatically accelerates the creation of new fat cells around the abdomen. Published in Science, the study found that these stem cells — called adipocyte progenitor cells — become highly active in middle-aged mice, generating far more fat cells than their younger counterparts. Crucially, this fat-producing ability was built into the older cells themselves, not the environment they were placed in. The findings help explain why belly fat accumulates with age even when total body weight stays relatively stable, and point toward potential new therapies targeting these cells to reduce abdominal fat and support healthier aging.
Detailed Summary
Belly fat is one of the most common and consequential changes that comes with aging, linked to increased risk of type 2 diabetes, heart disease, slower metabolism, and accelerated biological aging. Despite how common it is, the cellular mechanisms driving this shift have remained poorly understood — until now.
Researchers at City of Hope, working alongside scientists at UCLA, have identified a newly characterized type of stem cell that emerges with aging and appears to supercharge the body's production of new fat cells, particularly around the abdomen. Their findings were published in the journal Science. The cells in question are adipocyte progenitor cells (APCs), stem cells residing within fat tissue that can mature into fully developed fat cells.
The team conducted transplant experiments in mice, moving APCs from older animals into young mice and vice versa. APCs from older mice generated large numbers of new fat cells regardless of the age of the recipient animal. Young APCs transplanted into older mice produced far fewer. This result demonstrated that the aggressive fat-generating behavior was intrinsic to the older cells themselves — not simply a response to an aging body's internal environment.
Using single-cell RNA sequencing, the researchers mapped gene activity in individual cells and found that APCs were largely dormant in young mice but became highly active in middle-aged animals. This molecular shift appears to represent a biological switch that drives ongoing fat cell creation in addition to the simple enlargement of existing fat cells — a dual mechanism that helps explain why abdominal fat accumulates so persistently with age.
While the research was conducted primarily in mice with supporting human cell studies, the findings are promising. They suggest that targeting these age-activated stem cells could eventually yield new interventions for reducing belly fat and improving metabolic health. More research is needed to confirm these mechanisms fully in humans and to identify safe therapeutic strategies.
Key Findings
- A newly identified stem cell type activates during aging and drives aggressive new fat cell production in the abdomen.
- Older adipocyte progenitor cells retained their fat-producing power when transplanted into young mice, showing the trait is cell-intrinsic.
- Single-cell RNA sequencing revealed these stem cells shift from dormant to highly active in middle-aged compared to young mice.
- Belly fat may grow via two mechanisms with age: enlarging existing fat cells AND continuously creating new ones.
- The discovery points to a potential therapeutic target for reducing age-related abdominal fat and metabolic disease risk.
Methodology
This is a research summary based on a study published in the peer-reviewed journal Science, originating from City of Hope's Arthur Riggs Diabetes & Metabolism Research Institute. Evidence is drawn from mouse transplant experiments and single-cell RNA sequencing, supported by human cell studies. The source is credible and the journal is high-impact, though the article does not provide full methodological detail.
Study Limitations
The primary experiments were conducted in mice, and while human cell studies were included, full human clinical validation is pending. The article is a news summary and does not detail sample sizes, controls, or statistical methods. Readers should consult the primary Science publication for complete methodological assessment.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.
Enter your email to subscribe: